HITT for the Identification of Mild Traumatic Brain Injury
Key facts
- Who runs it
- Rebiscan, Inc.
- Where
- Philadelphia, United StatesSee the site
- Trial code
- Status
- Completed
- People taking part
- 10 people enrolled
- Started
- 1 Aug 2021
- Ended
- 31 Dec 2025
- Type of study
- Observational, 2 groups
- Treatments tested
- Head and Intraocular Trauma Tool
- SCAT-5
- Record updated
- 12 August 2026
Who can take part
- Age
- 13 years to 45 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 22 criteriaShow less
Who can take part
- Age 13-45 years
- Presents to the facility within 2 weeks of head trauma
- Able to provide informed consent; If minor, then able to provide parental consent and minor assent
- Able to participate in the examination, including the ability to follow simple instructions
- Fluency in English or Spanish
Who cannot take part
- Under the influence of alcohol or drugs
- Previous eye surgery
- Known eye movement disorder, including nystagmus
- Known optic nerve disease, including papilledema or optic neuropathy
- Known retinal disease, including macular degeneration or retinal degeneration
- History of neurosurgery
- History of stroke/brain hemorrhage, brain tumor, or epilepsy
- Diagnosed dementia or cognitive impairment requiring assistance for daily living
- Other condition(s) under the care of a neurologist
- Psychiatric hospitalization in the last 90 days
- Glasgow Coma Scale score of equal to or less than 13 at the time of study enrollment
- Visual acuity known to be 20/200 or less in either eye
- Known strabismus, amblyopia (lazy eye), or double vision
- Known cataract
- Any head trauma requiring medical attention from a physician within the last 6 months
- Subject considered unsuitable for participation in this clinical trial by PI, treating clinician, or study research staff
- Any minor brain injury regardless of loss of consciousness
Where in United States
- Penn Presbyterian Medical CenterPhiladelphia, United States
About the trial
What the trial wants to find out
Rebion has developed a device, the Rebion trauma tool (referred to as the head and intraocular trauma tool, or "HITT"), that detects ocular fixation and alignment using a binocular retinal scan. Preliminary data obtained from hospitalized patients with a clinically-confirmed traumatic brain injury (TBI) and uninjured controls indicates that the device can detect changes in ocular fixation, alignment, and saccades that are related to brain injury. This study seeks to evaluate the ability of the Rebion trauma tool to assess perturbations in eye movements resulting from TBI. The study will enroll 100 TBI patients and 100 controls.
The 2 groups in the trial
- TBI Patients
TBI participants 13 to 45 years of age, recruited from patients at a clinical research facility who present with head trauma. Clinical evaluation for the patient can be positive (target condition present) or negative (target condition absent) for mTBI. Enrollment is to occur within 2 weeks of the incident injury.
Treatment: Head and Intraocular Trauma Tool and SCAT-5
- Controls
Participants should not be part of the Intended Use Population. Subjects that present to the hospital, clinic or emergency department, either as a patient or non-patient, with no history of head trauma.
Treatment: Head and Intraocular Trauma Tool and SCAT-5
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Head and Intraocular Trauma Tool (HITT) for the Identification of Mild Traumatic Brain Injury
- Record updated
- 12 August 2026